Induction of Lethal Graft-versus-Host Disease by Anti-CD137 Monoclonal Antibody in Mice Prone to Chronic Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 3, 2009, Pages 306-314

  Kim, Wonyoung ^a   Kim, Juyang ^b   Jung, Daehee ^a   Kim, Hyuna ^a   Choi, Hye Jung ^b   Cho, Hong R ^b   Kwon, Byungsuk ^a,b  

^a University of Ulsan   (South Korea)

^b Ulsan University College of Medicine   (South Korea)

Author keywords

CD137; Chronic craft versus host disease; Graft versus host disease prophylaxis

Indexed keywords

CD137 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE MODEL; DISEASE PREDISPOSITION; DONOR; GRAFT SURVIVAL; HISTOPATHOLOGY; HOST CELL; IMMUNOMODULATION; MALE; MOUSE; NONHUMAN; PROPHYLAXIS; RADIATION DOSE; RADIATION INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T CELL DEPLETION; T LYMPHOCYTE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ACUTE DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD137; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; GRAFT VS HOST DISEASE; IMMUNE TOLERANCE; INFLAMMATION; INTERFERON-GAMMA; INTESTINE, LARGE; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TUMOR NECROSIS FACTOR-ALPHA; WHOLE-BODY IRRADIATION;

EID: 59349103120     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.11.035     Document Type: Article

References (47)

1. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 186 (1997) 47-55
2. Takahashi C., Mittler R.S., and Vella A.T. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol 162 (1999) 5037-5040
3. Mittler R.S., Bailey T.S., Klussman K., et al. Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J Exp Med 190 (1999) 1535-1540
4. Sun Y., Lin X., Chen H.M., et al. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J Immunol 168 (2002) 1457-1465
5. Sun Y., Chen H.M., Subudhi S.K., et al. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med 8 (2002) 1405-1413
6. Foell J., Strahotin S., O'Neil S.P., et al. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB × NZW F1 mice. J Clin Invest 111 (2003) 1505-1518
7. Seo S.K., Choi J.H., Kim Y.H., et al. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 10 (2004) 1088-1094
8. Foell J.L., Diez-Mendiondo B.I., Diez D.H., et al. Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance. Immunology 113 (2004) 89-98
9. + T cells. Blood 105 (2005) 2206-2213
10. Shao H., Fu Y., Liao T., et al. Anti-CD137 mAb treatment inhibits experimental autoimmune uveitis by limiting expansion and increasing apoptotic death of uveitogenic T cells. Invest Ophthalmol Vis Sci 46 (2005) 596-603
11. Fukushima A., Yamaguchi T., Ishida T., et al. Engagement of 4-1BB inhibits the development of experimental allergic conjunctivitis in mice. J Immunol 175 (2005) 4897-4903
12. Cho Y.S., Kwon B., Lee T.H., et al. 4-1BB stimulation inhibits allergen-specific immunoglobulin E production and airway hyper-reactivity but partially suppresses bronchial eosinophilic inflammation in a mouse asthma model. Clin Exp Allergy 36 (2006) 377-385
13. Polte T., Foell J., Werner C., et al. CD137-mediated immunotherapy for allergic asthma. J Clin Invest 116 (2006) 1025-1036
14. Sun Y., Blink S.E., Liu W., et al. Inhibition of Th2-mediated allergic airway inflammatory disease by CD137 costimulation. J Immunol 177 (2006) 814-821
15. Kim J., Kim H.J., Park K., et al. Costimulatory molecule-targeted immunotherapy of cutaneous graft-versus-host disease. Blood 110 (2007) 776-782
16. Zhang B., Maris C.H., Foell J., et al. Immune suppression or enhancement by CD137 costimulation during acute viral infection is time-dependent. J Clin Invest 117 (2007) 3029-3041
17. Jaffee B.D., and Claman H.N. Chronic graft-versus-host disease (GVHD) as a model for scleroderma, I: description of model systems. Cell Immunol 77 (1983) 1-12
18. McCormick L.L., Zhang Y., Tootell E., et al. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 163 (1999) 5693-5699
19. Zhang Y., McCormick L.L., Desai S.R., et al. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol 168 (2002) 3088-3099
20. Gilliam A.C. Update on graft-versus-host disease. J Invest Dermatol 123 (2003) 251-257
21. + T cells that survive irradiation regulate chronic graft-versus-host disease. Blood 104 (2004) 1565-1573
22. Krenger W., Cooke K.R., Sonis S.T., et al. Transplantation of polarized type 2 donor T cells reduces mortality caused by experimental graft-versus-host disease. Transplantation 62 (1996) 1278-1285
23. Hill G.R., Crawford J.M., Cooke K.R., et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90 (1997) 3204-3213
24. Blazar B.R., Kwon B.S., Panoskaltsis-Mortari A., et al. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients. J Immunol 166 (2001) 3174-3183
25. + T cells do not induce graft-versus-host disease. J Clin Invest 112 (2003) 101-108
26. Li J., Helm K., and Howell C.D. Contributions of donor CD4 and CD8 cells to liver injury during murine graft-versus-host disease. Transplantation 62 (1996) 1621-1628
27. Melero I., Johnston J.V., Shufford W.W., et al. NK1.1 cells express 4-1BB (CD137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 190 (1998) 167-172
28. Wilcox R.A., Chapoval A.I., Gorski K.S., et al. Cutting edge: expression of functional CD137 receptor by dendritic cells. J Immunol 168 (2002) 4262-4267
29. Futagawa T.H., Akiba H., Dodama T., et al. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol 14 (2002) 275-286
30. Heinisch I.V., Daigle I., Knophli B., et al. CD137 activation abrogates granulocyte-macrophage colony-stimulating factor-mediated anti-apoptosis in neutrophils. Eur J Immunol 30 (2000) 3441-3446
31. Schwarz H., Valbracht J., Tuckwell J., et al. ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages. Blood 85 (1995) 1043-1052
32. Heinisch I.V., Bizer C., Volgger W., et al. Functional CD137 receptors are expressed by eosinophils from patients with IgE-mediated allergic responses but not by eosinophils from patients with non-IgE-mediated eosinophilic disorders. J Allergy Clin Immunol 108 (2001) 21-28
33. Nishimoto H., Lee S.W., Hong H., et al. Costimulation of mast cells by 4-1BB, a member of the tumor necrosis factor receptor superfamily, with the high-affinity IgE receptor. Blood 106 (2005) 4241-4248
34. Lee S.J. New approaches for preventing and treating chronic graft-versus host disease. Blood 105 (2005) 4200-4206
35. Wehler T.C., Nonn M., Brandt B., et al. Targeting the activation-induced antigen CD1 37 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood 109 (2007) 365-373
36. Brochu S., Rioux-Massse B., Roy J., et al. Massive activation-induced cell death of alloreactive T cells with apoptosis of bystander postthymic T cells prevents immune reconstitution in mice with graft-versus-host disease. Blood 94 (1999) 390-400
37. Hamilton B.L. L3T4-positive T cells participate in the induction of graft-versus-host disease in response to minor histocompatibility antigens. J Immunol 139 (1989) 2511-2515
38. Kaplan D.H., Anderson B.R., McNiff J.M., et al. Target antigens determine graft-versus-host disease phenotype. J Immunol 173 (2004) 5467-5475
39. + T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 107 (2006) 2993-3001
40. Zhang L. The fate of adoptively transferred antigen-specific T cells in vivo. Eur J Immunol 26 (1996) 2208-2214
41. Zhang L., Miller R.G., and Zhang J. Characterization of apoptosis-resistant antigen-specific T cells in vivo. J Exp Med 183 (1996) 2065-2073
42. + T cells in the graft-versus-host reaction. J Immunol 163 (1999) 4780-4787
43. Dey B., Yang Y.-G., Preffer F., et al. The fate of donor T-cell receptor transgenic T cells with known host antigen specificity in a graft-versus-host disease model. Transplantation 68 (1999) 141-149
44. Gonzalez M., Quezada S.A., Blazar B.R., et al. The balance between donor T cell anergy and suppression versus lethal graft-versus-host disease is determined by host conditioning. J Immunol 169 (2002) 5581-5589
45. + T cell priming through in vivo ligation of glucocorticoid-induced TNF receptor. J Immunol 176 (2006) 5223-5231
46. + T cell tolerance through in vivo ligation of CD40 results in inhibition of chronic graft-versus-host disease (GVHD) and complete donor cell engraftment. J Immunol 181 (2008) 7380-7389
47. + cytolytic T lyphocytes in vivo. Blood 103 (2004) 177-184